In vitro in vivo agent development assays: evaluation of GLG-302, a STAT3 antagonist, in the prevention of mammary cancer; HHSN261201200021I - task order number: HHSN26100004 - university of alabama…

Ended Awarded Last action

Contract number
HHSN26100004
Awardee
Awarding agency
Obligated
$392,710

Award facts

Contract value 100% obligated
$392,710.44 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Birmingham, AL 35294, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 4 -$3,196
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $395,906

Description

In vitro in vivo agent development assays: evaluation of GLG-302, a STAT3 antagonist, in the prevention of mammary cancer; HHSN261201200021I - task order number: HHSN26100004 - university of alabama at birmingham - period of performance: 09/18/2013 - 09/17/2015

Quick answers

Who was awarded contract HHSN26100004?

HHSN26100004 was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on September 18, 2013.

How much is contract HHSN26100004 worth?

The government has obligated $392,710 on HHSN26100004.

Is contract HHSN26100004 an order under another contract?

Yes. HHSN26100004 is a delivery order under HHSN261201200021I, an indefinite delivery contract, on Preclinical Agent Development Assays 2012-2016.

Was contract HHSN26100004 competed?

The extent of competition for HHSN26100004 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award